Johnson & Johnson
Johnson & Johnson Announces Plan of Reorganization for Ovarian Cancer Claims
Summary
Johnson & Johnson announced a proposed Plan of Reorganization for the comprehensive and final resolution of all current and future claims related to ovarian cancer arising from cosmetic talc litigation in the United States, in exchange for the payment of approximately $6.475 billion over 25 years. This settlement resulted in an incremental charge of approximately $2.7 billion, reducing previously reported GAAP net earnings for the first quarter of 2024 from $5.4 billion to $3.3 billion, and earnings per share (EPS) from $2.20 to $1.34. The Company also revised its financial statements to reflect this settlement.
Profitelligence Alerts
Get alerts for JNJ
Be first to know when Johnson & Johnson files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Official SEC Documents
Advertisement